Yuviwel: Uses, Dosage, Side Effects, Warnings - Drugs. com Yuviwel is used to increase linear growth in children 2 years and older with achondroplasia with open epiphyses It is given once-weekly by subcutaneous injection Learn about side effects, the mechanism of action, and administration
Yuviwel for Achondroplasia - WebMD Yuviwel is an FDA-approved medicine to help improve growth rates in certain people with achondroplasia Here’s how it works
Achondroplasia treatment options - Medical News Today Achondroplasia is a common form of short-limbed dwarfism Learn about the goals of treatment, how to manage complications, and what new therapies researchers are developing
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for . . . “The approval of once-weekly YUVIWEL is a major step forward in the treatment of children with achondroplasia, giving physicians for the first time the option of prescribing a once-weekly medicine backed by compelling efficacy and excellent tolerability data from three randomized, double-blind, placebo-controlled clinical trials,” said
Ascendis Pharma Gains FDA Nod For Yuviwel And New Growth . . . FDA granted accelerated approval for Yuviwel, a once-weekly therapy for children with achondroplasia Yuviwel is the first weekly option in this indication, ending a competitor's monopoly with a
Navepegritide (Yuviwel®) for Children with Achondroplasia . . . Navepegritide (Yuviwel®) for Children with Achondroplasia: New Drugs and Therapeutics Written by Anna Ryabets-Lienhard, DO Edited by Neha Patel, DO and Emily Breidbart, MD On February 27th, 2026, the FDA approved Navepegritide (Yuviwel®), a C-natriuretic peptide (CNP) analog prodrug developed by Ascendis Pharmaceuticals using TransCon® CNP technology 1 The once‑weekly subcutaneous therapy
Ascendis wins FDA approval of dwarfism drug | BioPharma Dive The new drug, previously known as TransCon CNP and now Yuviwel, is a once-weekly injection cleared for children aged two and older with achondroplasia and open growth plates The treatment will compete with Voxzogo, a daily shot sold by BioMarin